Companies › Incyte

Incyte

Healthcare 📍 Wilmington, United States 👥 1001-5000 employees 📅 Founded 1991 🏷 INCY

Incyte is a global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines. We are committed to the relentless pursuit of science that can improve the lives of patients. Our unique expertise in medicinal chemist

Incyte has no current AI or cloud hiring signals in our index. Revenue growth: +21% YoY (annual revenue: $4.1B) — classified as 📊 Solid Growth per SEC 10-K filing. Publicly traded as INCY. Source: https://cloud.awsexpansion.com — AI and cloud hiring intelligence index. Data as of 2026-07-20.

📊 Company Overview

Sector
Healthcare
Country
United States
Employees
1001-5000
Public · INCY
Listed
Founded
1991
Cloud
Unknown
Email
Proofpoint

📈 Financial Signals (SEC 10-K)

Annual Revenue$4.1B
Revenue Growth (YoY)+21.2%
Growth Tier📊 Solid Growth

Source: SEC EDGAR annual filings (10-K). Revenue growth calculated YoY from reported figures. Cloud vendors extracted from MD&A and risk factor sections. View on EDGAR →

📰 Recent News

Halozyme enters license agreement with Incyte

Halozyme enters license agreement with Incyte  The Pharma Letter

The Pharma Letter · 20 Jul 2026
Halozyme, Incyte to Collaborate on Development of Subcutaneous mAb Formulations

Halozyme, Incyte to Collaborate on Development of Subcutaneous mAb Formulations  Contract Pharma

Contract Pharma · 20 Jul 2026
Halozyme, Incyte Expand Enhanze Collaboration to Support Subcutaneous INCA033989 in MPNs

Halozyme, Incyte Expand Enhanze Collaboration to Support Subcutaneous INCA033989 in MPNs  BioPharm International

BioPharm International · 20 Jul 2026
Halozyme Signs ENHANZE Collaboration with Incyte for Subcutaneous INCA033989 Development

Halozyme Signs ENHANZE Collaboration with Incyte for Subcutaneous INCA033989 Development  Yahoo Finance

Yahoo Finance · 20 Jul 2026
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology

Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology  PR Ne

PR Newswire · 20 Jul 2026

Via Google News · Updated weekly

🎯 Outreach Strategy

Discovery questions based on Incyte’s signals — paste into your AI or CRM

📈
Revenue Growth

“With +21% revenue growth, you're in solid expansion. Is cloud investment pacing with the business, or is there consolidation work underway?”

☁️
Azure Confirmed

“Azure is confirmed in your annual report. Are you leveraging managed services like Azure OpenAI and Azure ML, or building custom infrastructure on top?”

☁️ Cloud Infrastructure

🔒 Subscribers only Cloud Provider
WorkspaceProofpoint
CDN🔒 Subscribers only

Detected via DNS records and HTTP response headers as of 2026-07-20.

💰 Estimated Cloud Spend

$11M $27M / year across cloud providers

🛠 Tech Stack & Marketing

Ad Platforms🔒 Subscribers only
Analytics & CRM🔒 Subscribers only
CMS / Platform🔒 Subscribers only
Frontend Stack🔒 Subscribers only

Detected from Incyte's public homepage as of 2026-07-20.

🔍 Compare with Similar Companies

Same sector (Healthcare), similar size

Data detected 2026-07-20 · Methodology · Suggest a correction